A Phase III Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
Latest Information Update: 24 Jul 2023
At a glance
- Drugs Cisplatin (Primary) ; Paclitaxel (Primary) ; Toripalimab (Primary)
- Indications Oesophageal cancer; Squamous cell cancer; Thoracic neoplasms
- Focus Registrational; Therapeutic Use
- Sponsors Shanghai Junshi Biosciences
- 19 Jul 2023 The protocol has been amended as above-1) status has been changed from recruiting to active, not recruiting.2) Sequential assignment has been amended.
- 19 Jul 2023 Status changed from recruiting to active, no longer recruiting.
- 15 Dec 2022 Planned number of patients changed from 500 to 632.